Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Gothenburg, March 11, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that it has received a Notice of Allowance from the Japan Patent Office regarding its patent application for the CAR T-cell candidate ELC-401.

Once the patent has been granted, it can be maintained in force until 2041.

The patent protects Elicera's special antibodies that recognize and bind to the protein IL-13Ra2 (which is often present in large quantities on cancer cells, particularly brain tumors), as well as uses thereof in cancer treatment, such as CAR-T cell therapies.

The patent gives Elicera exclusive rights in Japan to develop and sell treatments based on these anti-IL-13Ra2 antibodies and related technologies for cancer treatment. This strengthens the company's protection for ELC-401 (its CAR-T cell candidate against glioblastoma) and other future products based on the same principle.